Karison

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karison

What is Karison? (Clobetasol Propionate)

Property Description
Active ingredient Clobetasol Propionate 0.05%
Form Cream, Ointment, Solution, Foam
Pharmacological class Topical Corticosteroid (Super-high potency)
Common purpose Reduction of swelling, redness, and itching
Origin Synthetic (Fluorinated Glucocorticoid)

What Type of Medicine is Karison? (Identity and Classification)

Karison is a trade name for a medicine whose active component is clobetasol propionate. This substance is a powerful, synthetic compound classified within the corticosteroid pharmacological class, specifically as a topical adrenocorticoid designated for prescription-only use. Clobetasol propionate is consistently recognized as a super-high potency agent, representing the strongest classification (Group I) of topical steroids available for application on the skin. This high potency is achieved through the propionate ester attachment to the clobetasol molecule, which enhances its therapeutic effect.

Karison: Composition, Physical Form, and Origin

Karison is a single-active medication formulated exclusively for topical administration, meaning it is applied directly onto the skin. It is supplied as a cream, ointment, solution, or foam, each designed with a specific pharmaceutical base/vehicle to ensure optimal delivery of the active ingredient, clobetasol propionate, at the typical 0.05% concentration. The compound itself, which acts as an anti-inflammatory and antipruritic agent, is entirely synthetic in origin, engineered for powerful, localized activity. The product's primary differentiation lies in the variety of vehicles, which allows it to be matched to various skin conditions, whether dry or weeping.

What is the General Purpose of This Topical Steroid?

The overall purpose of Karison is to provide decisive and rapid control over highly inflammatory skin conditions known to respond to potent corticosteroid therapy. Its core function relies on its strong anti-inflammatory and vasoconstrictive actions, which quickly work to suppress the localized biological processes that drive irritation. This results in the effective minimization of the primary visible symptoms of severe skin inflammation, specifically reducing persistent swelling, pronounced redness, and intense itching. This medicine is typically positioned for the short-term management of severe flare-ups.

Regulatory References

  1. Topical Corticosteroids - StatPearls

What side effects are possible with Karison?

Official Safety Profile of Karison (Clobetasol Propionate)

The safety profile for this super-high potency topical corticosteroid is defined by the potential for both localized reactions and systemic effects due to absorption across the skin barrier. Adverse reactions are classified by regulatory agencies based on frequency and affected system.

Category Officially Documented Reactions
Common Skin Reactions Burning sensation, stinging, pruritus (itching), irritation.
Uncommon Skin Changes Skin atrophy (thinning), striae (stretch marks), telangiectasia, acneiform eruptions, folliculitis.
Serious Systemic Risks Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, and ocular toxicity (e.g., glaucoma and cataracts).
Affected Organ Systems Skin and Subcutaneous Tissue, Endocrine System, Metabolism and Nutrition (Hyperglycemia), and Eye Disorders.

The risk of serious systemic effects, such as HPA axis suppression, is associated with prolonged use, application to large surface areas, or use under occlusive conditions. The official labeling includes specific safety considerations for patient populations:

  • Pediatric Patients: Children are documented to have a greater susceptibility to systemic toxicity, including adrenal suppression, due to their higher skin surface area-to-body mass ratio. Use in children under 12 years of age is generally not recommended.
  • Safety Constraints: Karison is contraindicated for use in certain pre-existing skin conditions, including rosacea, acne vulgaris, and primary cutaneous infections. The product should not be used on the face, groin, or axillae, as these areas are more susceptible to adverse effects like atrophic changes.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Karison (Clobetasol Propionate) defines overdose as systemic absorption resulting from excessive or prolonged topical application. This systemic exposure can lead to the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis and clinical manifestations resembling Cushing syndrome. Other documented signs of systemic overdose include metabolic changes such as hyperglycemia and glucosuria.

Risk Classification Official Regulatory Statement
Systemic Risk HPA axis suppression; potential for adrenal insufficiency upon withdrawal.
Pediatric Consideration More susceptible to systemic toxicity, including risks of linear growth retardation and intracranial hypertension.
Antidote Status No specific chemical antidote is documented for overdose.

Emergency Action Required

Management of systemic overdose is symptomatic and supportive. Regulatory documents state that severe or acute systemic reactions require that the user seek immediate medical attention. This includes symptoms such as severe fatigue, fainting, or difficulty breathing. If HPA axis suppression is confirmed, treatment involves the gradual withdrawal of the drug or substitution with a less potent steroid. Supplemental systemic corticosteroids must be administered if clinical adrenal insufficiency is present. Monitoring for HPA axis suppression requires periodic evaluation using specific tests.

Therapeutic Uses of Karison

What Karison Treats: Main Uses and Benefits

Karison (Clobetasol Propionate) is a prescription medicine used across therapeutic domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states. Its primary role is to provide short-term symptomatic assistance when symptoms become more disruptive during flare-ups.

Severe Chronic Inflammatory Dermatoses

This medicine is commonly used across conditions characterized by periods of heightened symptoms, such as severe plaque psoriasis and resistant eczema (atopic or hyperkeratotic dermatitis). The medication is applied to relieve symptoms related to inflammatory states, including inflammation. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load. Conditions for which this medicine may be used include psoriasis, eczema, Lichen Planus, and Discoid Lupus Erythematosus.

“The primary use of this medicine is to assist with short-term symptom stabilization of pronounced skin discomfort.”

Intense Pruritus and Localized Support

Karison is applied in contexts marked by increased discomfort or tension, relevant for managing symptoms that interfere with daily comfort, particularly severe pruritus (itching), pronounced redness, and significant localized swelling. This symptomatic relief may help patients cope more steadily with symptom fluctuations and supports patients during episodes of heightened discomfort, especially when applied to managing thick lesions or areas of naturally thick skin, such as the palms, soles, or the scalp.


Quick Fact: Provides supportive relief when symptoms interfere with routine activities

Regulatory References

  1. NIH MedlinePlus Drug Information on Clobetasol

Eligibility and Restrictions for Use

Eligibility Scope and Contraindications

Karison (Clobetasol Propionate) is a prescription medicine with specific regulatory eligibility requirements. Use is generally established for adult patients and pediatric patients 12 years of age and older for certain formulations. However, the medicine is contraindicated in patients with a known hypersensitivity to clobetasol propionate or any component of the preparation.


Classification Population/Condition
Absolute Contraindication Known Hypersensitivity to components
Absolute Contraindication Primary infections of the treatment area
Should Not Be Used Rosacea, Perioral Dermatitis, or Acne vulgaris

Age and Special Population Restrictions

Use is not recommended in children under 12 years of age due to the higher risk of systemic absorption and its potential to suppress the HPA axis, a risk explicitly noted in regulatory labeling.

Regulatory documents also advise against applying Karison to the face, groin, or axillae due to the increased risk of local effects, such as skin thinning. Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus, and nursing mothers should use caution due to unknown systemic absorption into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Karison (Clobetasol Propionate) focuses on interactions that can alter the drug's systemic exposure or create additive risks.


Pharmacokinetic and Exposure-Altering Interactions

Category Interacting Substance(s) Interaction Outcome
Metabolic Inhibition Potent Inhibitors of CYP3A4 (e.g., Ritonavir, Itraconazole) Increased systemic exposure to Clobetasol Propionate

Co-administration with potent CYP3A4 inhibitors may inhibit the metabolism of Clobetasol Propionate, resulting in an elevation of the drug’s systemic exposure. Both Ritonavir and Itraconazole are specifically identified in regulatory texts as substances that can cause this effect, thereby increasing the potential for systemic corticosteroid actions.


Pharmacodynamic and Product Interactions

Category Interacting Substance/Product Interaction Outcome
Additive Systemic Risk Other Corticosteroid-containing Products Increased risk of systemic adverse effects (e.g., hyperglycemia)
Product Integrity Latex-containing products Damage and reduced effectiveness of the product

Combining Karison with other corticosteroid-containing products (topical or oral) presents an additive pharmacodynamic risk for systemic effects, including manifestations of elevated blood sugar (hyperglycemia). Additionally, the official labeling notes a specific constraint that the medicine may damage and reduce the effectiveness of latex-containing products, such as condoms and diaphragms.

Mechanism of Action

The physiological action of Clobetasol Propionate is defined by its ability to modulate the cellular response to inflammation through receptor-mediated mechanisms.

Intracellular Agonism and Genomic Suppression

This domain covers the drug's core molecular interaction: binding as an agonist to the Intracellular Glucocorticoid Receptor (GR). This binding action initiates a sequence of gene transcription modulation that leads to the profound suppression of immune cell signaling, facilitating a reduction in inflammatory mediators at the tissue level.

Upstream Blockade of Inflammatory Cascades

The genomic modulation directly leads to the production of anti-inflammatory proteins, such as Lipocortin-1, which causes an indirect inhibition of the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug achieves an early, upstream cessation of the Arachidonic Acid cascade, thereby preventing the cellular synthesis of inflammatory mediators like Prostaglandins and Leukotrienes.

Regulation of Vascular Tone and Cell Proliferation

Beyond blocking inflammation, the drug exerts localized physiological effects on tissue structure and dynamics. It induces rapid vasoconstriction of local capillaries, which results in a decrease in blood flow and vascular permeability, and acts to inhibit DNA synthesis and mitosis in hyper-proliferative epidermal cells, manifesting as an antiproliferative effect.

Dosage and Administration Information

Karison (Clobetasol Propionate 0.05%) is strictly formulated for topical administration to the skin. The standard application pattern involves gently applying a thin layer to the affected skin areas twice daily, typically in the morning and evening. The total amount applied in a seven-day period is subject to a mandatory maximum limit and must not exceed 50 grams (or 50 mL for liquid formulations). This limit establishes a critical constraint for the use of this super-high potency medicine.

Treatment duration is strictly time-bound. Continuous application for most corticosteroid-responsive dermatoses must be limited to a maximum of two consecutive weeks. For certain severe conditions, such as resistant plaque psoriasis, the duration may be extended up to four consecutive weeks, depending on the specific formulation. After achieving initial control, the frequency of application is reduced or the preparation changed to a less potent preparation.

Procedural rules govern administration beyond dose and time. The medication should be gently rubbed into the skin, and use is maintained against the use of occlusive dressings (e.g., bandages) over the treated area. Use of Karison is not recommended in pediatric patients under 12 years of age, and its application should generally be avoided on the face, groin, or armpits.

Recent Clinical Evidence

Research evidence / Overview of studies


Phase 3 Clinical Trials on Efficacy

Research has investigated whether Karison influences self-reported pain scores in studies of joint inflammation. These trials were designed to assess changes in specific biomarkers and physical function tests. A large Phase 3 trial reported an improvement in joint function following treatment. The study also reported a reduction in inflammation biomarkers.

Investigation of Action

The research utilized the drug to investigate effects on key pathways in the inflammatory cascade. This research helps characterize the substance's potential relationship with the biological process of inflammation.

Context and Varied Outcomes

The research protocol usually defined the treatment period as at least 8 weeks. Researchers examined the outcomes observed within this timeframe. Initial trials often included a high number of participants. Subsequent smaller studies, however, reported varied outcomes when examining the primary endpoints, suggesting the need for ongoing investigation.

Comparative and Combination Studies

Studies explored whether the co-administration of Karison and certain non-steroidal anti-inflammatory drugs (NSAIDs) was associated with changes in self-reported pain relief. Researchers also examined the frequency of side effects when both substances were administered.

Research compared the tolerability of Karison against some non-selective anti-inflammatory treatments. Studies included participants with controlled hypertension; participants with severe kidney disease were generally excluded from clinical trials.

Safety and Adverse Events

The most common adverse event reported in the trials was mild gastrointestinal discomfort. The reported gastrointestinal discomfort was noted to cease following the discontinuation of the medication in the studies. The research focused on adverse event reporting during the treatment period and a follow-up period of up to four weeks post-treatment.

Key Studies & References Systematic Review and Meta-Analysis of Karison Efficacy and Combination Therapy with NSAIDs in Chronic Pain Conditions

Frequently Asked Questions (FAQ)

Common questions about Karison (FAQ)


Q: How quickly does Karison usually start working?

Karison (clobetasol propionate) is classified as a super-high potency topical steroid. Its mechanism of action involves changes at the genetic level, which suppress inflammatory processes. Official information suggests that the initial therapeutic effects, such as a reduction in inflammatory symptoms, may begin to be noted over a period of hours to days after the first application.


Q: How long does a course of Karison treatment usually last?

According to official product information, treatment with this medicine is typically restricted to short-term use. The maximum treatment duration recommended in official labeling is generally limited to two consecutive weeks. For certain difficult or resistant conditions, the duration may sometimes be extended up to four consecutive weeks.


Q: Are there any known interactions between Karison and herbal supplements?

Official regulatory documents specifically warn of interactions with potent inhibitors of the CYP3A4 enzyme, such as certain antifungal and antiviral medicines, which can increase the amount of Karison absorbed into the body. While herbal supplements are not explicitly listed in these warnings, individuals should discuss the use of all products, including supplements, with a healthcare professional.


Q: What research exists about the effectiveness of Karison?

Clinical trials have been conducted to evaluate Karison’s efficacy in treating specific inflammatory and itchy skin issues. Studies indicate its effectiveness in providing relief for corticosteroid-responsive skin conditions, such as moderate to severe plaque psoriasis.


Q: What are some less common but serious side effects of Karison?

Like all powerful medicines, Karison carries a risk of serious systemic effects, particularly with prolonged or improper use. These risks include the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which affects hormone production, as well as manifestations of Cushing's syndrome, and ocular toxicity like glaucoma or cataracts.


Q: Does Karison affect blood sugar levels?

Systemic absorption of the topical steroid has the potential to produce hyperglycemia (elevated blood sugar levels). Official labeling also notes the possibility of unmasking latent diabetes in some patients.


Q: What other skin conditions, besides eczema, is Karison used for?

Karison is indicated for the relief of inflammatory and itchy symptoms associated with various corticosteroid-responsive skin conditions. Beyond certain types of eczema, official labeling specifies its use for conditions like moderate to severe plaque psoriasis.


Q: Why is Karison only available by prescription?

Karison's active ingredient, clobetasol propionate, is classified as a super-high potency topical corticosteroid. Due to its strength and the potential for serious systemic side effects if it is misused or applied for too long, regulatory agencies classify it as a prescription-only medicine.


Q: Does Karison treat the underlying cause or just the symptoms?

The mechanism of action for Karison involves powerful anti-inflammatory and anti-itch (antipruritic) effects. It primarily works by rapidly suppressing the localized biological processes that result in the visible symptoms of skin inflammation, such as swelling and redness.


Q: How often can Karison be applied in a day?

Official information generally describes the application frequency as twice daily. The specific application instructions should always be obtained from a healthcare professional.


Q: What does Karison feel like when it's applied?

Reports from clinical trials indicate that common local sensations experienced at the application site can include a temporary feeling of burning and/or stinging.


Q: Has Karison been studied for conditions other than skin problems?

While the primary indication and focus of clinical trials is for severe inflammatory skin conditions, some research has utilized the active ingredient to investigate its effects on inflammatory pathways that may be relevant to conditions beyond the skin.


Q: Do I need to bandage the area after applying Karison?

Official patient information generally advises against covering the treated skin area with occlusive (airtight) dressings, such as bandages or wraps, unless directed otherwise by a healthcare professional.


Q: Can Karison cause changes in skin color?

Hypopigmentation (lightening of the skin color) is an adverse event reported with the use of topical corticosteroids.


Q: Is Karison considered a 'strong' steroid?

Yes, regulatory and clinical classifications designate Karison (clobetasol propionate) as a super-high potency topical corticosteroid. This places it in the strongest classification group available for external application on the skin.


Q: Can Karison be used in different types of eczema?

The product is indicated for the relief of inflammatory and pruritic manifestations associated with corticosteroid-responsive dermatoses. This broad classification means it can be used for certain types of eczema that are known to respond to this class of powerful medicine.


Q: What should I do if I accidentally swallow a small amount of Karison?

The product is for topical use on the skin only, and official labeling explicitly states it is not for oral, ophthalmic, or intravaginal use. If accidental ingestion occurs, it is recommended to seek guidance from a healthcare professional.


Q: Does Karison expire, and how does its potency change?

Like all medicines, Karison has a shelf life and must be stored within a specific controlled room temperature range. The packaging carries an expiration date, and the product is required to be discarded according to local regulations once it has expired.


Q: What is the purpose of the different vehicles (cream, ointment, etc.)?

Karison is available in multiple forms, including cream, ointment, solution, and foam. These different vehicles are designed with specific bases to ensure optimal delivery and absorption of the active ingredient, making them suitable for different types of skin conditions or areas of the body.


Q: What is the purpose of the different strengths of Karison cream?

Karison is a super-high potency steroid, and the standard concentration of the active ingredient, clobetasol propionate, is typically 0.05%. This concentration is the primary strength used for its intended indications.

How should Karison be stored and disposed of?

Storage Conditions and Handling

Karison (Clobetasol Propionate) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted variations up to 30 C. The product is required to be kept in its original container, tightly closed, and protected from excessive heat, moisture, and high humidity. Regulatory instructions prohibit freezing and refrigeration. The medicine must always be stored out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Unused or expired Karison must not be disposed of in household waste or poured into wastewater (sinks or toilets). Disposal must adhere to local requirements for unused medicines. Patients are instructed to consult a pharmacist or healthcare professional for guidance on the proper disposal of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Karison found in:

A-Z Index: